MiR-519d-3p REDUCES OSTEOCLASTOGENESIS BY LOWERING MMP2 AND SHIFTING OSTEOBLAST SIGNALING TOWARD OSTEOPROTEGERIN
DOI:
https://doi.org/10.15407/exp-oncology.2025.04.492Keywords:
miR-519d-3p, MMP2, osteoclastogenesis, osteoblast, conditioned medium, TRAPAbstract
Background. Paracrine crosstalk between tumor cells and bone-resident cells drives osteoclastogenesis in the metastatic bone niche. miR-519d-3p has been linked to suppression of matrix metalloproteinases. Aim. To test whether osteoblastic miR-519d-3p restrains tumor-conditioned osteoclastogenesis by lowering MMP2 expression and shifting signaling toward osteoprotegerin (OPG). Materials and Methods. Mouse osteoblasts (MC3T3-E1) were transfected with miR‑519d-3p mimic, inhibitor, or corresponding negative controls. Osteoblast-conditioned medium (OB-CM) was mixed 1:1 with MDA-MB-231 tumor-conditioned medium (231-CM) and applied to bone-marrow-derived macrophages for tartrate-resistant acid phosphatase (TRAP) staining. Osteoblastic MMP2 and OPG mRNAs were quantified by RT-qPCR, and a dual-luciferase system compared the wild-type vs seed-mutant MMP2 3′UTR reporters. Results. Relative to their controls, miR-519d-3p mimic OB-CM produced fewer TRAP-positive multinucleated osteoclasts, whereas inhibitor OB-CM produced more. In osteoblasts, the mimic decreased MMP2 mRNA, whereas the inhibitor increased it, and the changes in OPG mRNA were modest. Dual-luciferase assays did not show a reproducible wildtype–over-mutant selective repression by miR-519d-3p, indicating context-dependent or indirect regulation of MMP2. Conclusion. Elevating osteoblastic miR-519d-3p in vitro associated with lower MMP2 and an anti-osteoclastogenic paracrine output, suggesting a tractable microRNA-based approach to modulate the metastatic bone niche and warranting further validation in vivo.
References
Park Y, Sato T, Lee J. Functional and analytical recapitulation of osteoclast biology on demineralized bone paper. Nat Commun. 2023;14(1):8092. https://doi.org/10.1038/s41467-023-44000-9
Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38(1):12. https://doi.org/10.1186/ s13046-018-1001-2
Tauro M, Lynch C. Cutting to the chase: how matrix metalloproteinase-2 activity controls breast-cancer-to-bone metastasis. Cancers. 2018;10(6):185. https://doi.org/10.3390/cancers10060185
Veis DJ, O’Brien CA. Osteoclasts, master sculptors of bone. Annu Rev Pathol. 2023;18:257-281. https://doi. org/10.1146/annurev-pathmechdis-031521-040919
Ding J, Huang F, Wu G, et al. MiR-519d-3p suppresses invasion and migration of trophoblast cells via targeting MMP-2. PLOS ONE. 2015;10(3):e0120321. https://doi.org/10.1371/journal.pone.0120321
Abba M, Patil N, Allgayer H. MicroRNAs in the regulation of MMPs and metastasis. Cancers. 2014;6(2):625-645. https://doi.org/10.3390/cancers6020625
Yang K, Yang T, Yang T, et al. Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination. Front Oncol. 2022;12:995651. https://doi.org/10.3389/fonc.2022.995651
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
